FI56772C - Foerfarande foer framstaellning av en beredning foer behandling av onormala tarmtillstaond - Google Patents

Foerfarande foer framstaellning av en beredning foer behandling av onormala tarmtillstaond Download PDF

Info

Publication number: FI56772C
Authority: FI; Finland
Prior art keywords: preparation; colon; foer; tarmtillstaond; onormala
Prior art date: 1975-04-09

Application number

FI760948A

Other languages

English (en)

Finnish (fi)

Other versions

FI760948A7 (da

FI56772B (fi

Inventor

Curt Henry Appelgren

Conny Boerje Bogentoft

John Albert Sjoegren

Original Assignee

Haessle Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-04-09

Filing date

1976-04-07

Publication date

1980-04-10

1976-04-07 Application filed by Haessle Ab filed Critical Haessle Ab

1976-10-10 Publication of FI760948A7 publication Critical patent/FI760948A7/fi

1979-12-31 Publication of FI56772B publication Critical patent/FI56772B/fi

1980-04-10 Application granted granted Critical

1980-04-10 Publication of FI56772C publication Critical patent/FI56772C/fi

Links

238000002360 preparation method Methods 0.000 description 39
210000001072 colon Anatomy 0.000 description 17
239000000203 mixture Substances 0.000 description 15
239000008187 granular material Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000000034 method Methods 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
229920002125 Sokalan® Polymers 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
239000012530 fluid Substances 0.000 description 8
230000000968 intestinal effect Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
239000011230 binding agent Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
230000002496 gastric effect Effects 0.000 description 6
235000015099 wheat brans Nutrition 0.000 description 6
206010003011 Appendicitis Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
229920000084 Gum arabic Polymers 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
235000010489 acacia gum Nutrition 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000009472 formulation Methods 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
206010022998 Irritability Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000000205 acacia gum Substances 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000013872 defecation Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000002550 fecal effect Effects 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000010903 husk Substances 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
229940042003 metamucil Drugs 0.000 description 3
230000007659 motor function Effects 0.000 description 3
239000004584 polyacrylic acid Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000001148 spastic effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000008961 swelling Effects 0.000 description 3
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
206010010774 Constipation Diseases 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
241001528248 Frangula Species 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
244000134552 Plantago ovata Species 0.000 description 2
235000003421 Plantago ovata Nutrition 0.000 description 2
244000090599 Plantago psyllium Species 0.000 description 2
235000010451 Plantago psyllium Nutrition 0.000 description 2
229920000148 Polycarbophil calcium Polymers 0.000 description 2
239000009223 Psyllium Substances 0.000 description 2
235000021282 Sterculia Nutrition 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000002921 anti-spasmodic effect Effects 0.000 description 2
229940124575 antispasmodic agent Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000007844 bleaching agent Substances 0.000 description 2
235000010410 calcium alginate Nutrition 0.000 description 2
239000000648 calcium alginate Substances 0.000 description 2
229960002681 calcium alginate Drugs 0.000 description 2
229940095498 calcium polycarbophil Drugs 0.000 description 2
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
229960000541 cetyl alcohol Drugs 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
230000037406 food intake Effects 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
229940075507 glyceryl monostearate Drugs 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
230000007794 irritation Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
SJDACOMXKWHBOW-UHFFFAOYSA-N oxyphenisatine Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2NC1=O SJDACOMXKWHBOW-UHFFFAOYSA-N 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920002689 polyvinyl acetate Polymers 0.000 description 2
239000011118 polyvinyl acetate Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
229940070687 psyllium Drugs 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000007787 solid Substances 0.000 description 2
229940059107 sterculia Drugs 0.000 description 2
230000002522 swelling effect Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
206010000060 Abdominal distension Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
206010013554 Diverticulum Diseases 0.000 description 1
239000004129 EU approved improving agent Substances 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
229920000569 Gum karaya Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000934878 Sterculia Species 0.000 description 1
240000001058 Sterculia urens Species 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
244000290333 Vanilla fragrans Species 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
-1 fatty acid esters Chemical class 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
230000008676 import Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003871 intestinal function Effects 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)

FI760948A 1975-04-09 1976-04-07 Foerfarande foer framstaellning av en beredning foer behandling av onormala tarmtillstaond FI56772C (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE7504049A SE7504049L (sv)	1975-04-09	1975-04-09	Colonpreparation
SE7504049		1975-04-09

Publications (3)

Publication Number	Publication Date
FI760948A7 FI760948A7 (da)	1976-10-10
FI56772B FI56772B (fi)	1979-12-31
FI56772C true FI56772C (fi)	1980-04-10

Family

ID=20324216

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI760948A FI56772C (fi)	1975-04-09	1976-04-07	Foerfarande foer framstaellning av en beredning foer behandling av onormala tarmtillstaond

Country Status (12)

Country	Link
BE (1)	BE840552A (da)
DE (1)	DE2614296A1 (da)
DK (1)	DK153376A (da)
FI (1)	FI56772C (da)
FR (1)	FR2306710A1 (da)
GB (1)	GB1538123A (da)
IE (1)	IE42793B1 (da)
LU (1)	LU74732A1 (da)
NL (1)	NL7603600A (da)
NO (1)	NO761101L (da)
NZ (1)	NZ180552A (da)
SE (1)	SE7504049L (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS52139715A (en) *	1976-05-14	1977-11-21	Nippon Kayaku Co Ltd	Coated granules of alkali polyacrylate
FR2471186A1 (fr) *	1979-12-10	1981-06-19	Roussel Uclaf	Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4444761A (en) *	1981-05-04	1984-04-24	Syntex (U.S.A.) Inc.	Cellulose/carboxymethyl cellulose mixtures useful for controlling fecal output, and methods employing them
US4522804A (en) *	1983-01-03	1985-06-11	Verex Laboratories, Inc.	Constant release rate solid oral dosage formulations of propranolol
US4521401A (en) *	1983-01-03	1985-06-04	Verex Laboratories, Inc.	Constant release rate solid oral dosage formulations of quinidine
US4461759A (en) *	1983-01-03	1984-07-24	Verex Laboratories, Inc.	Constant release rate solid oral dosage formulations of veropamil
ES2039226T3 (es) *	1986-12-30	1993-09-16	American Cyanamid Company	Procedimiento para preparar composiciones que contienen policarbofil.
GB8817015D0 (en) *	1988-07-16	1988-08-17	Reckitt & Colmann Prod Ltd	Method of treatment
JPH0482832A (ja) *	1988-09-20	1992-03-16	Glaxo Group Ltd	医薬組成物
ES2048133T3 (es) *	1990-05-04	2000-01-16	Perio Prod Ltd	Sistema de descarga de farmacos para el colon.
IL98087A (en) *	1990-05-04	1996-11-14	Perio Prod Ltd	Preparation for dispensing drugs in the colon
DE9212938U1 (de) *	1992-09-25	1992-11-26	Boehringer Ingelheim Gmbh, 6507 Ingelheim	Calciumpolycarbophil-Zubereitung zur Einnahme hoher Wirkstoffdosen
US5840332A (en) *	1996-01-18	1998-11-24	Perio Products Ltd.	Gastrointestinal drug delivery system
AU2018251210B2 (en)	2017-04-14	2025-01-23	Gelesis S.r.l.	Compositions and methods for treating or preventing gut permeability-related disorders

1975
- 1975-04-09 SE SE7504049A patent/SE7504049L/xx unknown
1976
- 1976-03-30 NO NO761101A patent/NO761101L/no unknown
- 1976-03-31 DK DK153376A patent/DK153376A/da not_active IP Right Cessation
- 1976-04-02 DE DE19762614296 patent/DE2614296A1/de not_active Withdrawn
- 1976-04-06 NL NL7603600A patent/NL7603600A/xx not_active Application Discontinuation
- 1976-04-07 FI FI760948A patent/FI56772C/fi not_active IP Right Cessation
- 1976-04-08 FR FR7610342A patent/FR2306710A1/fr active Granted
- 1976-04-08 NZ NZ180552A patent/NZ180552A/xx unknown
- 1976-04-08 GB GB14390/76A patent/GB1538123A/en not_active Expired
- 1976-04-09 IE IE749/76A patent/IE42793B1/en unknown
- 1976-04-09 BE BE165981A patent/BE840552A/xx unknown
- 1976-04-09 LU LU74732A patent/LU74732A1/xx unknown

Also Published As

Publication number	Publication date
GB1538123A (en)	1979-01-10
NO761101L (da)	1976-10-12
FI760948A7 (da)	1976-10-10
BE840552A (fr)	1976-10-11
FR2306710B1 (da)	1979-07-13
NZ180552A (en)	1978-07-28
DK153376A (da)	1976-10-10
IE42793B1 (en)	1980-10-22
FI56772B (fi)	1979-12-31
LU74732A1 (da)	1977-02-04
FR2306710A1 (fr)	1976-11-05
DE2614296A1 (de)	1976-10-21
IE42793L (en)	1976-10-09
NL7603600A (nl)	1976-10-12
SE7504049L (sv)	1976-10-10

Legal Events

Date	Code	Title	Description
2004-08-31	MM	Patent lapsed	Owner name: AB HAESSLE

Publication	Publication Date	Title
US4511561A (en)	1985-04-16	Laxative composition comprising psyllium seeds and senna fruits
US4470975A (en)	1984-09-11	Method and composition for the elimination of water from an animal body
DE60026459T2 (de)	2006-11-09	Simethicon enthaltendes Abführmittel
WO2021104155A1 (zh)	2021-06-03	一种解酒护肝水凝胶片及其制备方法和应用
US11213559B2 (en)	2022-01-04	Formulation for treatment of irritable bowel disease
NO761101L (da)	1976-10-12
CN106667915B (zh)	2019-09-13	一种用于治疗仔猪腹泻的黄芩苷铝干混悬剂
FI75095B (fi)	1988-01-29	Foerfarande foer framstaellning avfoeringsmedel baserat pao ratamonfroen och sennafrukter.
CN101491493A (zh)	2009-07-29	阿魏酸哌嗪缓释药物制剂
RU2559590C2 (ru)	2015-08-10	Применение полисахаридов для лечения стресса и тревоги
CN106474132B (zh)	2019-06-28	聚普瑞锌在制备治疗或减轻放化疗所致消化道并发症及肠易激综合征药物中的应用
CN100381136C (zh)	2008-04-16	一种治疗便秘的药物组合物及其制剂和制备方法
CN108619283B (zh)	2020-07-10	一种用于改善脂质代谢、减少内脏脂肪的组合物
CN102716128A (zh)	2012-10-10	一种治疗哮喘的药用组合物
CN119345223A (zh)	2025-01-24	含有菊粉和岩藻多糖的药物组合物、药物联合及其应用
US2990327A (en)	1961-06-27	Composition and method for treating biliary dyskinesia
CN1895520B (zh)	2011-06-29	一种胃铋镁颗粒及其制备方法
CN117481345B (zh)	2024-04-05	一种具有肠胃调节功能的壳寡糖组合物及功能糖
CN104587316B (zh)	2018-05-08	抗痛风组合物及其制备方法和应用
KR100849806B1 (ko)	2008-07-31	팽윤성 식이섬유와 리파제 억제제를 포함하는 비만 억제조성물 및 이의 제조 방법
CN105687163A (zh)	2016-06-22	一种米拉贝隆缓释微丸及其制备方法
WO2020104987A1 (en)	2020-05-28	Composition for use in the prevention and/or symptomatic treatment of irritable bowel syndrome
CN110522022B (zh)	2023-01-06	润肠通便的黄秋葵粉及其制备方法
CN107137491A (zh)	2017-09-08	一种治疗甲状腺肿大的药物组合物及其制备方法
CN103565748B (zh)	2014-10-22	一种聚乙二醇4000散剂